Treatment intensification with currently available androgen receptor signalling inhibitors improves survival in men with hormone/castration-sensitive prostate cancer (CSPC), according to results presented at the ESMO Congress 2021. The PEACE-1 study showed that addition of abiraterone acetate plus prednisone (AAP) produced clear survival improvements in patients with metastatic prostate cancer, the conference heard. A second trial, the STAMPEDE ...
Survival benefits with androgen receptor signalling inhibitors seen in prostate cancer
By Michael Woodhead
23 Sep 2021